At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-Center, Phase 2, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution (0.25% Novel Formulation) Compared to Vehicle in Subjects With Dry Eye Disease
In Brief
A Phase 2 clinical trial evaluating Reproxalap Ophthalmic Solution (0.25% Novel Formulation) QID to BID and Vehicle Ophthalmic Solution (0.25% Novel Formulation) QID to BID for Dry Eye. Completed, enrolled 206 participants across 1 site.
Detailed Summary
A Multi-Center, Phase 2, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution (0.25% Novel Formulation) Compared to Vehicle in Subjects with Dry Eye Disease
Study Details
Timeline
Interventions
Reproxalap Opthalmic Solution (0.25% Novel Formulation) administered QID for four weeks, followed by BID administration for eight weeks
Vehicle Ophthalmic Solution administered QID for four weeks, followed by BID administration for eight weeks